<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Clin Exp Metastasis</journal-id>
      <journal-title>Clinical &amp; Experimental Metastasis</journal-title>
      <issn pub-type="ppub">0262-0898</issn>
      <issn pub-type="epub">1473-7276</issn>
      <publisher>
        <publisher-name>Springer Netherlands</publisher-name>
        <publisher-loc>Dordrecht</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">18357507</article-id>
      <article-id pub-id-type="pmc">2413104</article-id>
      <article-id pub-id-type="publisher-id">9152</article-id>
      <article-id pub-id-type="doi">10.1007/s10585-008-9152-8</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research Paper</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Serum proteome analysis for profiling protein markers associated with carcinogenesis and lymph node metastasis in nasopharyngeal carcinoma</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Liao</surname>
            <given-names>Qiulin</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Zhao</surname>
            <given-names>Liang</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff2">2</xref>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Chen</surname>
            <given-names>Xiaodong</given-names>
          </name>
          <xref ref-type="aff" rid="Aff4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Deng</surname>
            <given-names>Yongjian</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name name-style="western">
            <surname>Ding</surname>
            <given-names>Yanqing</given-names>
          </name>
          <address>
            <phone>+86-20-61642148</phone>
            <fax>+86-20-61642148</fax>
            <email>dyq@fimmu.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff2">2</xref>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <aff id="Aff1"><label>1</label>Department of Pathology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China </aff>
        <aff id="Aff2"><label>2</label>Key Laboratory of Functional Proteomics and Molecular Tumor Pathology of Guangdong Province, Southern Medical University, Guangzhou, China </aff>
        <aff id="Aff3"><label>3</label>Department of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515 China </aff>
        <aff id="Aff4"><label>4</label>Department of Pathology, General Hospital of Guangzhou Military Command, Guangzhou, China </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>21</day>
        <month>3</month>
        <year>2008</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>6</month>
        <year>2008</year>
      </pub-date>
      <volume>25</volume>
      <issue>4</issue>
      <fpage>465</fpage>
      <lpage>476</lpage>
      <history>
        <date date-type="received">
          <day>8</day>
          <month>12</month>
          <year>2007</year>
        </date>
        <date date-type="accepted">
          <day>16</day>
          <month>2</month>
          <year>2008</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; The Author(s) 2008</copyright-statement>
      </permissions>
      <abstract>
        <p>Nasopharyngeal carcinoma (NPC), one of the most common cancers in population with Chinese or Asian progeny, poses a serious health problem for southern China. It is unfortunate that most NPC victims have had lymph node metastasis (LNM) when first diagnosed. We believe that the 2D based serum proteome analysis can be useful in discovering new biomarkers that may aid in the diagnosis and therapy of NPC patients. To filter the tumor specific antigen markers of NPC, sera from 42 healthy volunteers, 27 non-LNM NPC patients and 37 LNM NPC patients were selected for screening study using 2D combined with MS. Pretreatment strategy, including sonication, albumin and immunoglobulin G (IgG) depletion, was adopted for screening differentially expressed proteins of low abundance in serum. By 2D image analysis and MALDI-TOF-MS identification, twenty-three protein spots were differentially expressed. Three of them were further validated in the sera using enzyme-linked immunosorbent assay (ELISA). Our research demonstrates that HSP70, sICAM-1 and SAA, confirmed with ELISA at sera and immunohistochemistry, are potential NPC metastasis-specific serum biomarkers which may be of great underlying significance in clinical detection and management of NPC.</p>
      </abstract>
      <kwd-group>
        <title>Keywords</title>
        <kwd>Nasopharyngeal carcinoma</kwd>
        <kwd>Serum proteome</kwd>
        <kwd>Carcinogenesis</kwd>
        <kwd>Lymph node metastasis</kwd>
      </kwd-group>
      <custom-meta-wrap>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; Springer Science+Business Media B.V. 2008</meta-value>
        </custom-meta>
      </custom-meta-wrap>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1" sec-type="introduction">
      <title>Introduction</title>
      <p>Nasopharyngeal carcinoma (NPC) is a rare malignancy in most parts of the world, though it is highly prevalent in Southern Asia, where the incidence is about a 100-fold higher than in other populations. It is one of the most confusing, commonly misdiagnosed and poorly understood diseases. Previous studies show that the cancer is an Epstein-Barr virus-associated malignancy with a remarkable racial and geographical distribution. The etiology of NPC is thought to be associated with a complex interaction of genetic, viral, environmental and dietary factors. Thanks to the advancements in genomics, proteomics and bioinformatics in recent decades, the etiology, carcinogenesis and progression of the disease is better understood. Research into these components may unravel the pathways in NPC development and potentially decipher the molecular characteristics of the malignancy [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. NPC is an insidious tumor and is usually at the stage of metastasis involving lymph nodes or other organs before it can be found. Thus early and accurate diagnosis is very important for therapy and prognosis of NPC patients. Unfortunately, no effective method of accurately diagnosing new-onset NPC is available now. We presume if specific serum biomarkers associated with NPC metastasis can be identified on the basis of advancements in genomics, proteomics and bioinformatics, an approach to the early detection and monitoring of NPC may be found.</p>
      <p>2D comparative proteome analysis is a new technology for the separation and identification of disease-specific proteins, and it has been applied successfully to screen potential biomarkers for NPC in cell lines and tumor tissues [<xref ref-type="bibr" rid="CR3">3</xref>&#x2013;<xref ref-type="bibr" rid="CR8">8</xref>]. In our previous studies, we employed proteomic techniques to study protein changes of CNE2, a poorly differentiated squamous carcinoma cell line of human NPC cells, induced by 12-<italic>O</italic>-Tetradecanoyl-phorbol-13-acetate (TPA). It is likely that TPA promotes NPC in necessary cooperation with EBV, or that it may function as an antiproliferative or differentiative revulsant in noninitiated cells [<xref ref-type="bibr" rid="CR4">4</xref>]. However, if a marker can be detected only in surgical specimens, its clinical significance is limited, especially for early screening or diagnosis. Recently, Saeid R. et&#xA0;al. reported their pioneering work on NPC serum analysis by 2D without any pretreatment, revealing the enhanced expression of relatively abundant proteins as ceruloplasmin (CPL) [<xref ref-type="bibr" rid="CR9">9</xref>]. In order to find relatively low-abundant serum proteins which may be more valuable in predicting NPC progression, we pretreated serum with sonication, albumin and IgG depletion before 2D analysis. By comparing 2D image analyses for healthy volunteers, non-LNM NPC and LNM NPC patients, we may identify the differentially expressed proteins so that specific serum biomarkers associated with NPC metastasis can be found.</p>
    </sec>
    <sec id="Sec2" sec-type="materials|methods">
      <title>Materials and methods</title>
      <sec id="Sec3">
        <title>Subjects</title>
        <p>Serum samples from 42 healthy volunteers and 64 NPC patients were available for comparative proteomic analysis. Samples from NPC patients were obtained before any clinical treatment. All the patients had a nasopharyngeal biopsy and NPC was confirmed by two independent pathologists unaware of the patient&#x2019;s condition. Careful medical examinations and CT scan determined non-LNM cases and LNM cases in the NPC patients. Clinical data of all the subjects for 2D and ELISA are shown in Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>. In the screening study, serum samples from the same group were pooled to smooth intrinsic individual differences and enhance common characteristic traits only related to disease status [<xref ref-type="bibr" rid="CR10">10</xref>], aliquoted, and stored at &#x2212;80&#xB0;C before analysis. In the validation study, 26 of the patients received a mean of 17.8&#xA0;months of follow-up (range, 6&#x2013;22&#xA0;months) after radiotherapy and/or chemotherapy. Six of the followed-up patients died of NPC, and the other survived the follow-up period.
<table-wrap id="Tab1"><label>Table&#xA0;1</label><caption><p>Serum samples in the study</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2"/><th align="left" colspan="3">Samples for 2-DE</th><th align="left" colspan="3">Samples for ELISA</th></tr><tr><th align="left">Healthy</th><th align="left" colspan="2">NPC</th><th align="left">Healthy</th><th align="left" colspan="2">NPC</th></tr></thead><tbody><tr><td align="left">Lymph node status</td><td align="left">/</td><td align="left">Negative</td><td align="left">Positive</td><td align="left">/</td><td align="left">Negative</td><td align="left">Positive</td></tr><tr><td align="left">Number</td><td align="left">42</td><td align="left">27</td><td align="left">37</td><td align="left">30</td><td align="left">27</td><td align="left">30</td></tr><tr><td align="left">Gender (Male/Female)</td><td align="left">22/20</td><td align="left">21/6</td><td align="left">23/14</td><td align="left">15/15</td><td align="left">21/6</td><td align="left">20/10</td></tr><tr><td align="left">Age (&#xB1;SD)</td><td align="left">42&#xA0;&#xB1;&#xA0;7.9</td><td align="left">43&#xA0;&#xB1;&#xA0;10.9</td><td align="left">50.5&#xA0;&#xB1;&#xA0;11.7</td><td align="left">42.5&#xA0;&#xB1;&#xA0;8.9</td><td align="left">43&#xA0;&#xB1;&#xA0;10.9</td><td align="left">47.6&#xA0;&#xB1;&#xA0;10.2</td></tr></tbody></table></table-wrap></p>
      </sec>
      <sec id="Sec4">
        <title>Depletion of high-abundance proteins</title>
        <p>Sigma-Aldrich ProteoPrep<sup>&#xAE;</sup> Immunoaffinity Albumin and IgG Depletion Kit was used for depletion of proteins, albumin and IgGs, allowing visualization of co-migrating proteins with albumin and IgG on a 2D gel and also higher sample loads for improved visualization of lower abundance proteins. A total of 30&#xA0;&#x3BC;l of serum was diluted with 100&#xA0;&#x3BC;l of equilibration buffer from the depletion kit (Sigma) and sonicated using four ultrasonic bursts of 15&#xA0;s each. Between sonications, the samples were chilled on ice. Then serum albumin and IgG was depleted according to the manufacturer&#x2019;s instructions. After collection of the bound proteins, the majority (&gt;95%) of the unbound proteins were left in the depleted serum sample. Modified Bradford assay was used to measure the protein concentrations of all serum samples [<xref ref-type="bibr" rid="CR11">11</xref>].</p>
      </sec>
      <sec id="Sec5">
        <title>2D analysis</title>
        <p>The Immobiline Dry strip (pH 4&#x2013;7, length 17&#xA0;cm, Bio-Rad) was rehydrated with 600&#xA0;mg protein in 350&#xA0;ml rehydration buffer containing 7&#xA0;M urea, 2&#xA0;M thiourea, 4% CHAPS, 65&#xA0;mM DTT, 5&#xA0;mM tributylphosphine, 1% IPG buffer and 0.002% bromophenol blue for 14&#xA0;h at room temperature. IEF was performed using Protean IEF cell (Bio-Rad, Hercules, CA, USA) with a total of 70&#xA0;kVh. Then the strip was subjected to two-step equilibration in equilibration buffer containing 6&#xA0;M urea, 30% glycerol, 2% SDS and 50&#xA0;mM Tris&#x2013;HCl (pH 6.8) with 1%&#xA0;w/v DTT for the first step, and 2.5%&#xA0;w/v iodoacetamide for the second step. The second-dimensional SDS-PAGE gel (13% T, 2.7% C, and 20&#xA0;&#xD7;&#xA0;20&#xA0;&#xD7;&#xA0;1&#xA0;mm<sup>3</sup>) was carried out using a Protean II xi 2D cell (Bio-Rad) according to the following procedure: 30&#xA0;min at a constant current of 12&#xA0;mA followed by 24&#xA0;mA per gel until the bromophenol blue front reached the bottom of the gel. Subsequently the gels were stained with MS accommodated silver staining [<xref ref-type="bibr" rid="CR12">12</xref>]. 2D of each sample was run in triplicate to minimize run-to-run variation. The silver-stained 2D gel were scanned using a Power-Look 1100 imaging scanner (Umax, Dallas, TX, USA) and analyzed using PDQuest 7.1 software package (Bio-Rad).</p>
      </sec>
      <sec id="Sec6">
        <title>In-gel enzymatic digestion</title>
        <p>Protein spots were excised from gel with an operating knife blade, destained twice with 30&#xA0;mM potassium ferricyanide and 100&#xA0;mM sodium thiosulfate (1:1&#xA0;v/v) and then equilibrated in 50&#xA0;mM NH<sub>4</sub>HCO<sub>3</sub> to pH 8.0. After dehydrating with ACN and drying in N<sub>2</sub> at 37&#xB0;C for 20&#xA0;min, the gel pieces were rehydrated in 15&#xA0;ml trypsin solution (10&#xA0;&#x3BC;g/ml in 25&#xA0;mM NH<sub>4</sub>HCO<sub>3</sub>) at 4&#xB0;C for 30&#xA0;min and incubated at 37&#xB0;C overnight. Peptides were extracted twice using 0.1% TFA in 50% CAN and dried with N<sub>2</sub>.</p>
      </sec>
      <sec id="Sec7">
        <title>MALDI-TOF-MS identification</title>
        <p>The peptide mixtures were solubilized with 0.5% TFA, with saturated &#x3B1;-cyano-4-hydroxy-trans-cinnamic (CHCA) solution in 0.1% TFA/50% acetonitrile as the matrix and analyzed using M@LDI R (Micromass, Manchester, UK). Mass spectra were externally calibrated with lock mass 2,465.199&#xA0;Da and internally calibrated with autodigested peaks of trypsin (MH+: 2,211.105&#xA0;Da).</p>
      </sec>
      <sec id="Sec8">
        <title>Protein identification and database searching</title>
        <p>Protein identification using peptide mass fingerprinting (PMF) was performed by the MASCOT search engine (<ext-link ext-link-type="uri" xlink:href="http://www.matrixscience.com/">http://www.matrixscience.com/</ext-link>, MatrixSicence Ltd., London, UK) against the MSDB protein database. The errors in peptide masses were in the range of 25&#xA0;ppm. One missed tryptic cleavage site per peptide was allowed during the search. Proteins matching more than four peptides and with a MASCOT score higher than 64 were considered significant (<italic>P</italic>&#xA0;&lt;&#xA0;0.05). Carboamidomethylation of cysteine was selected as the static modification and oxidation of methionine as the differential modification. Protein identification results were filtered with peakErazor software.</p>
      </sec>
      <sec id="Sec9">
        <title>Enzyme-linked immunosorbent assay (ELISA) confirmation</title>
        <p>ELISAs were conducted to confirm the protein identification and differential expression of sICAM-1, SAA and HSP70 in sera from the three groups. Measurements were done by commercially available ELISA kits (StressXpress Hsp70 ELISA Kit: EKS-700B, Stressgen Biotechnologies, Victoria; High sensitivity sICAM-1 ELISA Kit: BMS241, Bender Medsystems Company, Australian; Human SAA ELISA Kit: EL10015, YES Biotech Laboratories Ltd, Canada), in accordance with the manufacturer&#x2019;s instructions. All sera were stored at &#x2212;80&#xB0;C before they were measured. Both standards and samples were run in duplicate. The main protocols were as follows: monoclonal coating antibody was adsorbed onto microwells; target protein present in the sample or standard bound to antibodies was adsorbed to the microwells; second antibody was added and bound to target protein captured by the first antibody; following incubation unbound enzyme was removed during a wash step; a color reaction was formed and absorbance was measured at 450&#xA0;nm. The standard curve was used to determine the concentration of target protein in an unknown sample.</p>
      </sec>
      <sec id="Sec10">
        <title>Immunohistochemistry (IHC) assay</title>
        <p>The previous studies showed that sICAM-1 in serum could be released by membrane-associated ICAM-1 of cancer cell [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. However, SAA is synthesized and secreted into serum by hepatocytes in the liver during the acute phase [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. In the present study, therefore, expressions of only HSP70 and ICAM-1 were detected in tissue by IHC assay. Three-micrometer sections of paraffin-embedded tissues were cut for a prior antigen retrieval step in boiling 10&#xA0;mM citrate buffer pH 6 for 20&#xA0;min. The fixed tissues were subjected to immunostaining using an ultrasensitive S-P technique (MaiXin, China). Briefly, the slides were incubated overnight at 4&#xB0;C with goat anti-ICAM and anti-HSP70 polyclonal antibody (1:200) (Wuhan Boster Biological Technology Co., Ltd., China). The concentrations of the primary antibodies used have been optimized previously. After washing with PBS three times, they were treated with biotin-conjugated second antibody before adding streptavidin-peroxidase. For color reaction, diaminobenzidine (DAB) was used. All series included positive controls. For negative controls, the antibody was replaced by PBS. To evaluate the expression, the cellular localization of immunoreactivity was determined and scored for both intensity (negative, weak, moderate and strong) and proportion (5&#x2013;25, 26&#x2013;50, 51&#x2013;75 and 76&#x2013;100%) of stained cells. To allow comparison of immunostaining with pathological stage and metastasis for each cancer, integer values were assigned to the scores of intensity (0&#x2013;3) and proportion of tumor cells stained (0&#x2013;4). If the evaluations did not agree, the specimens were reevaluated and then classified according to the assessments given, most frequently, by the observers. The proportion and intensity scores were then added to obtain a total score, which was labeled as one of the four following categories: (a) high positive (+++), total score of 6&#x2013;7; (b) moderate positive (++), total score of 4&#x2013;5; (c) low positive (+), total score of 2&#x2013;3; (d) negative (&#x2212;), total score of 0&#x2013;2.</p>
      </sec>
      <sec id="Sec11">
        <title>Statistical analysis</title>
        <p>All the analyses performed were descriptive. The serum levels of protein expressions were compared using one-way ANOVA test. Associations between immunohistochemical scores and clinicopathological variables of tissue specimens were evaluated by Fisher&#x2019;s exact test or &#x3C7;<sup>2</sup> test. PDQuest software was used to establish a master gel representing each group [<xref ref-type="bibr" rid="CR17">17</xref>]. For differential expression of matched gels, protein spots whose intensities were either increased or decreased two-fold or greater were marked and then confirmed by manual inspection of all relevant 2D gel, not only those included in the matchsets, to ensure consistency. Quantitative analysis was performed using the Student&#x2019;s <italic>t</italic>-test among three groups of gels. All statistical analysis was performed with SPSS 10.0 software and <italic>P</italic> value &lt;0.05 were considered statistically significant.</p>
      </sec>
    </sec>
    <sec id="Sec12" sec-type="results">
      <title>Results</title>
      <sec id="Sec13">
        <title>Quantitative comparison and identification of protein spots on 2D gels</title>
        <p>Among the three groups, we found twenty-three spots significantly altered (<italic>P&#xA0;</italic>&lt;&#xA0;0.05) or absent/emergent, 13 of which were identified successfully (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>). The corresponding detailed differential expression patterns are shown in Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>a. Quantitative comparison and MS identification of the 13 differentially expressed proteins are shown in Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>b and summarized in Table&#xA0;<xref rid="Tab2" ref-type="table">2</xref>, respectively. Overall, transferrin (TRF) and transthyretin (TTR) were down-regulated and 12-lipoxygenase (12-LOX), serum amyloid A1 protein precursor (SAA), soluble intercellular adhesion molecule-1 (sICAM-1) and lysine-specific histone demethylase1 (LSD1) were up-regulated in two NPC groups compared with the healthy group. Furthermore, increased expression levels of 12-LOX, sICAM-1 and SAA were observed in LNM NPC as compared with non-LNM NPC. However, heat shock protein 70 (HSP70) and cytochrome P450 (CYP450) were expressed significantly and constantly only in LNM NPC patients. The MALDI-TOF-MS mass spectra are shown in Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>.
<fig id="Fig1"><label>Fig.&#xA0;1</label><caption><p>Representative 2D patterns of albumin and IgG depleted serum from healthy (<bold>a</bold>), non-LNM NPC (<bold>b</bold>) and LNM NPC groups (<bold>c</bold>). In the 2D images, spots &#x2018;1&#x2013;10&#x2019; indicate up-regulation and &#x2018;11&#x2013;13&#x2019; down-regulation in NPC group. Black arrows indicate protein spots that were identified successfully by MS</p></caption><graphic position="anchor" xlink:href="10585_2008_9152_Fig1_HTML" id="MO1"/></fig><fig id="Fig2"><label>Fig.&#xA0;2</label><caption><p>Detailed 2D patterns of the thirteen differentially expressed proteins among healthy, non-LNM and LNM NPC groups (<bold>a</bold>). Corresponding gel positions are shown in Fig. <xref rid="Fig1" ref-type="fig">1</xref>. Magnified 2D maps demonstrating the different expressions of selected proteins are listed in Table <xref rid="Tab2" ref-type="table">2</xref>. The densitometric analysis of each protein was calculated from nine different gels using PDQuest 7.1 software package (<bold>b</bold>). Each bar represents the mean&#xA0;&#xB1;&#xA0;S.D. of intensity, with significant differences between groups found by two-tailed student&#x2019;s-test. Note that this panel has a different vertical (y) axis and a break in the axis to accommodate the poor performance of the subject spot No.6. The break region is from 5000 to 6000. *<italic>P</italic>&#xA0;&lt;&#xA0;0.05, compared with healthy group; **<italic>P</italic>&#xA0;&lt;&#xA0;0.05, compared with non-LNM NPC group</p></caption><graphic position="anchor" xlink:href="10585_2008_9152_Fig2_HTML" id="MO2"/></fig><table-wrap id="Tab2"><label>Table&#xA0;2</label><caption><p>Identification results of differentially expressed proteins among healthy volunteers, non-LNM NPC and LNM NPC patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">No.<sup>a</sup></th><th align="left">Protein description</th><th align="left">MSDB ID</th><th align="left">Protein level<sup>b</sup></th><th align="left">MASCOT score<sup>c</sup></th><th align="left">Sequence coverage<sup>d</sup> (%)</th><th align="left">Theoretical Mr/p<italic>I</italic><sup>e</sup></th></tr></thead><tbody><tr><td align="left">1</td><td align="left">Ovochymase precursor</td><td align="left">Q7RTY7</td><td align="left">&#x2191;</td><td char="." align="char">116</td><td char="." align="char">52</td><td char="." align="char">124,947/8.67</td></tr><tr><td align="left">2</td><td align="left">Arachidonate 12-lipoxygenase</td><td align="left">AAA51587</td><td align="left">&#x2191;</td><td char="." align="char">193</td><td char="." align="char">68</td><td char="." align="char">75,694/5.82</td></tr><tr><td align="left">3</td><td align="left">sICAM-1</td><td align="left">Q99930</td><td align="left">&#x2191;</td><td char="." align="char">112</td><td char="." align="char">54</td><td char="." align="char">4270/6.40</td></tr><tr><td align="left">4</td><td align="left">Cytochrome P450</td><td align="left">Q53EX9</td><td align="left">&#x2191;</td><td char="." align="char">207</td><td char="." align="char">57</td><td char="." align="char">55,635/6.83</td></tr><tr><td align="left">5</td><td align="left">Serum amyloid A1 protein precursor</td><td align="left">YLHUS</td><td align="left">&#x2191;</td><td char="." align="char">170</td><td char="." align="char">85</td><td char="." align="char">13,524/6.28</td></tr><tr><td align="left">6</td><td align="left">Hemoglobin beta subunits are s-nitrosylated</td><td align="left">1BUWB</td><td align="left">&#x2191;</td><td char="." align="char">207</td><td char="." align="char">55</td><td char="." align="char">15,565/6.76</td></tr><tr><td align="left">7</td><td align="left">E1A 10S protein</td><td align="left">Q9YLA2</td><td align="left">&#x2191;</td><td char="." align="char">143</td><td char="." align="char">69</td><td char="." align="char">28,493/4.09</td></tr><tr><td align="left">8</td><td align="left">Lysine-specific histone demethylase 1</td><td align="left">O60341</td><td align="left">&#x2191;</td><td char="." align="char">172</td><td char="." align="char">58</td><td char="." align="char">93,358/6.11</td></tr><tr><td align="left">9</td><td align="left">KIAA1622 protein</td><td align="left">Q9HCF0</td><td align="left">&#x2191;</td><td char="." align="char">78</td><td char="." align="char">61</td><td char="." align="char">102,351/8.42</td></tr><tr><td align="left">10</td><td align="left">Heat shock 70&#xA0;kDa protein (HSP70)</td><td align="left">Q6G1F9</td><td align="left">&#x2191;</td><td char="." align="char">157</td><td char="." align="char">53</td><td char="." align="char">68,161/4.88</td></tr><tr><td align="left">11</td><td align="left">Transferrin</td><td align="left">Q9NQB8</td><td align="left">&#x2193;</td><td char="." align="char">167</td><td char="." align="char">67</td><td char="." align="char">77,050/6.81</td></tr><tr><td align="left">12</td><td align="left">UPF0366 protein C11orf67</td><td align="left">AAD40378</td><td align="left">&#x2193;</td><td char="." align="char">104</td><td char="." align="char">58</td><td char="." align="char">12,798/8.58</td></tr><tr><td align="left">13</td><td align="left">Transthyretin</td><td align="left">AAA61181</td><td align="left">&#x2193;</td><td char="." align="char">87</td><td char="." align="char">69</td><td char="." align="char">12,836/5.35</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>The numbers indicate the spot positions in 2D gel as shown in Figs.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref> and <xref rid="Fig2" ref-type="fig">2</xref></p><p><sup>b</sup>&#x2191;, up-regulation in NPC patients; &#x2193;, down-regulation in NPC patients</p><p><sup>c</sup>By MALDI-TOF MS analysis</p><p><sup>d</sup>Calculated by amino acid count</p><p><sup>e</sup>Calculated from the database entry without any processing</p></table-wrap-foot></table-wrap><fig id="Fig3"><label>Fig.&#xA0;3</label><caption><p>PMF of protein spots No. 3, 5 and 10, respectively, representing sICAM-1 (panel A), SAA (panel B), and HSP70 (panel C), which were expressed differentially between the groups of non-LNM and LNM NPC (MASCOT scores are 65, 85 and 78, respectively, <italic>P&#xA0;</italic>&lt;&#xA0;0.05)</p></caption><graphic position="anchor" xlink:href="10585_2008_9152_Fig3_HTML" id="MO3"/></fig></p>
      </sec>
      <sec id="Sec14">
        <title>ELISA confirmation</title>
        <p>Figures&#xA0;<xref rid="Fig4" ref-type="fig">4</xref> and <xref rid="Fig5" ref-type="fig">5</xref> show the ELISA results of sICAM-1, SAA and HSP70 performed in the three groups. There were statistically significant differences between health and NPC groups (<italic>P&#xA0;</italic>&lt;&#xA0;0.01) as well as between non-LNM and LNM NPC groups (<italic>P&#xA0;</italic>&lt;&#xA0;0.05) (Fig.&#xA0;<xref rid="Fig4" ref-type="fig">4</xref>). And with the TNM stage advanced, the serum levels of sICAM-1 and HSP70, were detected significantly elevated, but that of SAA not (Fig.&#xA0;<xref rid="Fig5" ref-type="fig">5</xref>). Furthermore, bivariate correlation analysis showed a significant relationship between the serum levels of the three proteins (<italic>P&#xA0;</italic>&lt;&#xA0;0.01). The follow-up showed that the serum levels of sICAM-1 and HSP70, but not of SAA, were strongly associated with NPC mortality (Student&#x2019;s <italic>t</italic>-test, <italic>P&#xA0;</italic>=&#xA0;0.001, 0.001 and 0.132, respectively). Our ELISA findings were consistent with results of 2D and silver-staining.
<fig id="Fig4"><label>Fig.&#xA0;4</label><caption><p>Quantitative comparison of sICAM-1, HSP70 and SAA in sera among healthy, non-LNM NPC and LNM NPC groups. Each bar represents the mean&#xA0;&#xB1;&#xA0;S.D. of the concentration, with significant differences between groups found by one-way ANOVA test. Note that this panel has a different vertical (y) axis and a break in the axis to accommodate the poor performance of the subject SAA. The break region is from 500 to 4500&#xA0;&#x3BC;g/l. *<italic>P</italic>&#xA0;&lt;&#xA0;0.05, compared with healthy group; **<italic>P</italic>&#xA0;&lt;&#xA0;0.05, compared with non-LNM NPC group</p></caption><graphic position="anchor" xlink:href="10585_2008_9152_Fig4_HTML" id="MO4"/></fig><fig id="Fig5"><label>Fig.&#xA0;5</label><caption><p>Quantitative comparison of sICAM-1, HSP70 and SAA in sera among NPC patients at different TNM stage. Each bar represents the mean&#xA0;&#xB1;&#xA0;S.D. of the concentration, with significant differences between groups found by one-way ANOVA test. Note that this panel has a different vertical (y) axis and a break in the axis to accommodate the poor performance of the subject SAA. The break region is from 600 to 2000&#xA0;&#x3BC;g/l. *<italic>P</italic>&#xA0;&lt;&#xA0;0.05, compared with NPC patients at TNM stage I; **<italic>P</italic>&#xA0;&lt;&#xA0;0.05, compared with NPC patients at TNM stage II; ***<italic>P</italic>&#xA0;&lt;&#xA0;0.05, compared with NPC patients at TNM stage III</p></caption><graphic position="anchor" xlink:href="10585_2008_9152_Fig5_HTML" id="MO5"/></fig></p>
      </sec>
      <sec id="Sec15">
        <title>IHC assay</title>
        <p>In NPC patients, HSP70 and ICAM-1 were observed in tumor cells but not in stromal, endothelial or inflammatory cells. The immunoreactivity was located in both membrane and cytoplasm for ICAM-1 and only in cytoplasm for HSP70 (Fig.&#xA0;<xref rid="Fig6" ref-type="fig">6</xref>). The immunoreactivities of HSP70 and ICAM-1 were observed in 37 (64.9%) and 43 (75.4 %) of the 57 cases of NPC, respectively. The correlation of positive rates showing HSP70 and ICAM-1 immunoreactivity with clinicpathological characteristics of the cases is summarized in Table&#xA0;<xref rid="Tab3" ref-type="table">3</xref>. Statistically, positive expression rates of HSP70 and ICAM-1 were significantly correlated with lymph node metastasis (LNM) of NPC. Furthermore, we found that positive expression rates of ICAM-1 (6/6, 100%) and HSP70 (5/6, 83.3%) were high in the cases that died of NPC during the follow-up period (<italic>P&#xA0;</italic>&gt;&#xA0;0.05). The results manifested that ICAM-1 and HSP70 expressions were strongly associated with NPC metastasis and mortality, indicating poor prognosis.
<fig id="Fig6"><label>Fig.&#xA0;6</label><caption><p>Immunohistochemical detection of HSP70 and ICAM-1 in NPC (Magnification &#xD7;200). The immunoreactivity was located in both membrane and cytoplasmic stainings for ICAM-1 but only in cytoplasmic staining for HSP70. The black arrows indicate the target proteins stained in brown-yellow in the NPC nest. The red arrow in E shows negative immunoreactivity of normal nasopharyngeal epithelia. <bold>a</bold>, negative expression of HSP70; <bold>b</bold> and <bold>c</bold>, positive expressions of HSP70; <bold>d</bold>, negative expression of ICAM-1; <bold>e</bold> and <bold>f</bold>, positive expressions of ICAM-1; <bold>a</bold>, <bold>b</bold>, <bold>d</bold> and <bold>e</bold>, non-LNM NPC; C and F, LNM NPC</p></caption><graphic position="anchor" xlink:href="10585_2008_9152_Fig6_HTML" id="MO6"/></fig><table-wrap id="Tab3"><label>Table&#xA0;3</label><caption><p>Characteristics of NPC patients dependent on ICAM-1 and HSP70 expressions</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Characteristics</th><th align="left" rowspan="2">Number</th><th align="left" colspan="3">ICAM-1 expression</th><th align="left" colspan="3">HSP70 expression</th></tr><tr><th align="left">Negative</th><th align="left">Positive (%)</th><th align="left"><italic>P</italic> value</th><th align="left">Negative</th><th align="left">Positive (%)</th><th align="left"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left" colspan="8">Gender</td></tr><tr><td align="left">&#xA0;&#xA0;&#xA0;&#xA0;Male</td><td char="." align="char">41</td><td char="." align="char">9</td><td char="(" align="char">32 (78.0) </td><td char="." align="char">0.464</td><td char="." align="char">15</td><td char="(" align="char">26 (63.4) </td><td char="." align="char" rowspan="2">0.704</td></tr><tr><td align="left">&#xA0;&#xA0;&#xA0;&#xA0;Female</td><td char="." align="char">16</td><td char="." align="char">5</td><td char="(" align="char">11 (68.8) </td><td char="." align="char"/><td char="." align="char">5</td><td char="(" align="char">11 (68.8) </td></tr><tr><td align="left" colspan="8"><italic>Age</italic></td></tr><tr><td align="left" colspan="8">Mean (45.4) </td></tr><tr><td align="left">&#xA0;&#xA0;&#xA0;&#xA0;&lt;45&#xA0;years</td><td char="." align="char">26</td><td char="." align="char">7</td><td char="(" align="char">19 (73.1) </td><td char="." align="char">0.704</td><td char="." align="char">9</td><td char="(" align="char">17 (65.4) </td><td char="." align="char" rowspan="2">0.945</td></tr><tr><td align="left">&#xA0;&#xA0;&#xA0;&#xA0;&#x2265;45&#xA0;years</td><td char="." align="char">31</td><td char="." align="char">7</td><td char="(" align="char">24 (77.4) </td><td char="." align="char"/><td char="." align="char">11</td><td char="(" align="char">20 (64.5) </td></tr><tr><td align="left" colspan="8">Lymph node status</td></tr><tr><td align="left">&#xA0;&#xA0;&#xA0;&#xA0;Positive</td><td char="." align="char">30</td><td char="." align="char">3</td><td char="(" align="char">27 (90.0) </td><td char="." align="char">0.012</td><td char="." align="char">5</td><td char="(" align="char">25 (83.3) </td><td char="." align="char" rowspan="2">0.002</td></tr><tr><td align="left">&#xA0;&#xA0;&#xA0;&#xA0;Negative</td><td char="." align="char">27</td><td char="." align="char">11</td><td char="(" align="char">16 (59.3) </td><td char="." align="char"/><td char="." align="char">15</td><td char="(" align="char">12 (44.4) </td></tr><tr><td align="left" colspan="8">TNM stage</td></tr><tr><td align="left">&#xA0;&#xA0;&#xA0;&#xA0;I&#xA0;+&#xA0;II</td><td char="." align="char">24</td><td char="." align="char">11</td><td char="(" align="char">13 (54.2) </td><td char="." align="char">0.002</td><td char="." align="char">12</td><td char="(" align="char">12 (50.0) </td><td char="." align="char" rowspan="2">0.044</td></tr><tr><td align="left">&#xA0;&#xA0;&#xA0;&#xA0;III&#xA0;+&#xA0;IV</td><td char="." align="char">33</td><td char="." align="char">3</td><td char="(" align="char">30 (90.9) </td><td char="." align="char"/><td char="." align="char">8</td><td char="(" align="char">25 (75.8) </td></tr><tr><td align="left" colspan="8">Survival rate</td></tr><tr><td align="left">&#xA0;&#xA0;&#xA0;&#xA0;Survival</td><td char="." align="char">20</td><td char="." align="char">6</td><td char="(" align="char">14 (70)</td><td char="." align="char">0.280</td><td char="." align="char">6</td><td char="(" align="char">14 (70)</td><td char="." align="char" rowspan="2">1.000</td></tr><tr><td align="left">&#xA0;&#xA0;&#xA0;&#xA0;Mortality</td><td char="." align="char">6</td><td char="." align="char">0</td><td char="(" align="char">6 (100)</td><td char="." align="char"/><td char="." align="char">1</td><td char="(" align="char">5 (83.3)</td></tr></tbody></table><table-wrap-foot><p><italic>Note</italic>: Values in parentheses are percentages</p></table-wrap-foot></table-wrap></p>
      </sec>
    </sec>
    <sec id="Sec16" sec-type="discussion">
      <title>Discussion</title>
      <p>Serum is a complex body fluid, containing a large diversity of proteins. More than 10,000 different proteins are present in the human serum and many of them are secreted or shed by cells during different physiology or pathology processes [<xref ref-type="bibr" rid="CR18">18</xref>]. Consequently, proteomics has raised great expectations for the discovery of biomarkers to improve diagnosis or classification of a wide range of diseases, including cancers [<xref ref-type="bibr" rid="CR19">19</xref>]. Serum is expected to be an excellent source of protein biomarkers because it circulates through, or comes in contact with, all tissues. During this contact it is likely to pick up proteins secreted or shed by tissues, which has recently been tested and confirmed [<xref ref-type="bibr" rid="CR20">20</xref>]. However, serum has been termed as the most complex human proteome [<xref ref-type="bibr" rid="CR21">21</xref>] with considerable differences in the concentrations of individual proteins, ranging from several milligrams to less than one pictogram per milliliter [<xref ref-type="bibr" rid="CR22">22</xref>]. Another analytical challenge for biomarker discovery arises from the high variability in the concentration and state of modification of some human plasma proteins between different individuals [<xref ref-type="bibr" rid="CR23">23</xref>]. Despite these limitations, human serum holds immense diagnostic potential. In the last decade, several large-scale projects have been initiated, aimed at characterizing the human plasma/serum proteome.</p>
      <p>In the mean time, several serum proteomic studies on NPC have been reported. Cho et&#xA0;al. performed protein chip profiling analysis with surface-enhanced laser desorption ionization time-of-flight mass spectrometry (SELDI-TOF-MS) technology on sera from NPC patients and demonstrated that SAA may be a potentially usefully biomarker for NPC [<xref ref-type="bibr" rid="CR24">24</xref>]. However, the technology for discovery of new cancer biomarkers has recently been questioned for its flaws, such as its qualitative nature, high identification error rate, poor reproducibility and nonspecific absorption matrices [<xref ref-type="bibr" rid="CR25">25</xref>&#x2013;<xref ref-type="bibr" rid="CR27">27</xref>]. 2D-based comparative proteome analysis, though a new technology for the separation and identification of disease-specific proteins, has been applied successfully to screen potential biomarkers for NPC in cell lines and tumor tissues [<xref ref-type="bibr" rid="CR3">3</xref>&#x2013;<xref ref-type="bibr" rid="CR8">8</xref>].</p>
      <p>Recently, Saeid et&#xA0;al. reported their pioneering work on NPC serum analysis by 2D, revealing the enhanced expression of such relatively abundant proteins as ceruloplasmin (CPL) [<xref ref-type="bibr" rid="CR9">9</xref>]. However, in 2D study, abundant proteins, such as albumin and IgG, that account for approximately 60&#x2013;97% of the total serum proteins [<xref ref-type="bibr" rid="CR28">28</xref>], mask other proteins that migrate to the surrounding areas and limit the loading amount of serum. As albumin and IgG are known to function as carriers and transporters of important proteins such as hormones, cytokines, and lipoproteins within the blood [<xref ref-type="bibr" rid="CR29">29</xref>&#x2013;<xref ref-type="bibr" rid="CR31">31</xref>], the depletion of these two highly abundant proteins may result in the loss of potentially important proteins bound to them at the same time. In order to release those adsorbed or bound proteins, we sonicated the diluted sera before the depletion and desalting steps as suggested by Quero et&#xA0;al. [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]. The improvements we made in sample preparation enabled us to find some valuable low abundant proteins.</p>
      <p>Of the 13 successfully identified protein spots, we focused on 10 up-regulated proteins in NPC for further validation. We also accumulated certain knowledge about three proteins by literature profiling. Finally, we decided to further investigate sICAM-1, HSP70 and SAA, which seemed more associated with our research interest, using both ELISA and IHC to validate their differential expressions. Intriguingly, most of these identified proteins have been reported to be associated with carcinogenesis and tumor metastasis. Our research is herein chiefly concerned with the functional implications of the three proteins to NPC at the serum level.</p>
      <p>Although the source of sICAM-1 has not been fully elucidated, researches show it can be released by cancer cells [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>] as well as by peripheral blood mononuclear, endothelial, and fibroblastic cells [<xref ref-type="bibr" rid="CR34">34</xref>]. Proteolytic cleavage of membrane-bound ICAM-1 may be the most likely mechanism for the generation of sICAM-1 [<xref ref-type="bibr" rid="CR35">35</xref>]. In patients with certain malignancies, the serum sICAM-1 titers have been found elevated in association with tumor growth and distant metastasis of malignant melanoma [<xref ref-type="bibr" rid="CR36">36</xref>], lung [<xref ref-type="bibr" rid="CR37">37</xref>], breast [<xref ref-type="bibr" rid="CR38">38</xref>], gastric [<xref ref-type="bibr" rid="CR39">39</xref>], hepatocellular [<xref ref-type="bibr" rid="CR40">40</xref>], and colorectal cancers [<xref ref-type="bibr" rid="CR41">41</xref>]. Poor survival of cancer patients correlated with a high level of serum sICAM-1 has also been demonstrated [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>]. In our study, the positive expression of tissue ICAM-1 and levels of serum sICAM-1 were significantly correlated to the presence, progression, metastasis and mortality of NPC. sICAM-1 possesses most of the necessary extracellular structures to retain the functional activities of ICAM-1 [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]. It has been reported that ICAM-1 on the surface of cancer cells or antigen presenting cells (i.e., macrophages) is a costimulatory factor that stabilizes T-cell receptor-mediated binding between these cells and T lymphocytes [<xref ref-type="bibr" rid="CR42">42</xref>]. sICAM-1 would work as an immunosuppressive agent by blocking LFA-1 on T lymphocytes, thus rendering it less available for binding with ICAM-1 on the surface of cancer cells [<xref ref-type="bibr" rid="CR43">43</xref>]. In this manner, the shedding of sICAM-1 may speed up the metastatic process by escaping host immune surveillance. This, probably, presents an additional potential mechanism accounting for high serum levels of sICAM-1 in NPC patients who have metastasized via hematogenous and lymphatic routes. As serum sICAM-1 may be useful for monitoring hematogenous metastasis, measuring the serum sICAM-1 level might be potentially significant in clinic.</p>
      <p>SAA is an acute-phase protein with various isoforms in a molecular mass range of 11&#x2013;14. In normal individuals, SAA is produced by hepatocytes in the liver [<xref ref-type="bibr" rid="CR16">16</xref>]. After secreted into serum, it rapidly binds to high-density lipoprotein, with 90% of the protein particles bound [<xref ref-type="bibr" rid="CR15">15</xref>]. A review of the literature shows that only a low level of SAA can be found in the sera of healthy individuals, despite the ubiquitous nature of SAA [<xref ref-type="bibr" rid="CR44">44</xref>]. This is in sharp contrast to the patients with neoplastic diseases, such as those with renal [<xref ref-type="bibr" rid="CR45">45</xref>] and colorectal [<xref ref-type="bibr" rid="CR46">46</xref>] cancers, who showed dramatic elevation of serum SAA. The prognostic significance of SAA for other cancers has also been found by conventional radioimmunoassay, in line with the findings of this study [<xref ref-type="bibr" rid="CR47">47</xref>]. Cho et&#xA0;al. demonstrated that SAA may be a potentially usefully biomarker for NPC [<xref ref-type="bibr" rid="CR24">24</xref>]. The report fully confirmed relatively huge concentrations of SAA in serum (0.2&#x2013;2&#xA0;g/l) that are thousands of times higher than classical cancer biomarkers (such as CEA, PSA, CA125, etc.) originating from tumor cells. In a similar way, we further confirmed that serum SAA was much elevated in NPC patients, particularly at the process of lymph node metastases when compared with non-LNM patients. However, such biomarkers (acute-phase reactants) are not commonly considered as cancer-specific ones and expected to be elevated in other malignant diseases or inflammatory diseases as well [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. In previous reports, SAA was found elevated in different malignancies, such as cancers of kidney, colon and prostate, as well as in leukemias and lymphomas [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR48">48</xref>]. Therefore, SAA may represent a cancer epiphenomenon, unlikely to be of much clinical use in diagnosing and monitoring cancer [<xref ref-type="bibr" rid="CR49">49</xref>], but it will be interesting to explore whether the rapid production of SAA in the liver or the epithelia of different organs [<xref ref-type="bibr" rid="CR50">50</xref>] may be related to the stimulation by cytokines abundantly present in the NPC cells. It is also meaningful to investigate how SAA is produced at different stages of clinical manifestation in NPC patients.</p>
      <p>HSP70 is the main protein produced during cellular response to varied stresses, such as heat shock, ischemia/reperfusion, and oxidative changes [<xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR52">52</xref>]. Because HSP70 confers cell protection against different stresses, it has been hypothesized that it plays a protective role in tumor growth in&#xA0;vivo [<xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR54">54</xref>]. Indeed, HSP70 is overexpressed in human tumors of varied origins [<xref ref-type="bibr" rid="CR55">55</xref>], such as colorectal [<xref ref-type="bibr" rid="CR56">56</xref>], breast [<xref ref-type="bibr" rid="CR57">57</xref>, <xref ref-type="bibr" rid="CR58">58</xref>], prostate [<xref ref-type="bibr" rid="CR59">59</xref>], liver [<xref ref-type="bibr" rid="CR60">60</xref>] cancers and melanoma [<xref ref-type="bibr" rid="CR61">61</xref>]. LNM and poor survival of cancer patients correlated with HSP70 overexpression has also been documented [<xref ref-type="bibr" rid="CR57">57</xref>, <xref ref-type="bibr" rid="CR58">58</xref>, <xref ref-type="bibr" rid="CR61">61</xref>&#x2013;<xref ref-type="bibr" rid="CR63">63</xref>]. It is suggested that HSP70 is needed for <italic>in&#xA0;vivo</italic> tumor progression. In addition, HSP70 may be released from tumor cells involving involves both active secretion and passive release from necrotic cells [<xref ref-type="bibr" rid="CR64">64</xref>]. Physiological mechanisms include co-secretion in exosomes of HSC70 with TRF and the active HSP70 secretion by the nonclassical pathway employed by cytokines [<xref ref-type="bibr" rid="CR65">65</xref>]. Therefore, HSP70 is detectable in serum so that it could potentially be used as a biomarker for diagnosis or disease classification. Abe et&#xA0;al. reported that HSP70 is a marker of prostate cancer, and may be used in conjunction with PSA to identify patients with early-stage prostate cancer [<xref ref-type="bibr" rid="CR59">59</xref>]. However, to the best of our knowledge, the association between serum level of HSP70 and NPC status has not been reported. Since our findings demonstrated that there was a modest association between serum HSP70 level and NPC staging, the serum HSP70 level should not be considered as an independent prognostic factor in NPC patients, although it might be a prognostic predictor by univariate analysis. In short, serum HSP70 may have an adjunctive clinical value in monitoring tumor progression and evaluating prognosis in NPC patients, though its clinical application as a major tumor marker is limited.</p>
      <p>In conclusion, our serum proteomic analysis, using a comprehensive pretreatment strategy, provides a practical and exemplary tool of screening progression-associated serum proteins in NPC research. After comparing 2D image analyses for healthy volunteers, non-LNM NPC and LNM NPC patients, we successfully identified 13 differentially expressed protein spots. We further explored the differential expressions of three of the proteins, namely, sICAM-1, HSP70 and SAA, by ELISA at serum and IHC at tissue, though more work should be completed to pinpoint the direct correlation between serum level of sICAM and HSP70 and their expression level in the tissues. We suggest that the three proteins may be potential serum biomarkers which can serve as effective target points for early diagnosis and therapy of NPC patients, though further clinical research should be done before the potential come true.</p>
    </sec>
  </body>
  <back>
    <ack>
      <title>Acknowledgment</title>
      <p>This work was financially supported by National Key Basic Research Program of China (973 Program) (No. 2001CB510207), Key Science and Technology Research Program of Guangdong Province (No. 2003A308401) and Natural Science Foundation of Guangdong Province (No. 5200512). We also thank Professor Liang Ping for his critical reading and revision of the manuscript.</p>
      <p><bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.</p>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kumar</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Mahanta</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Aetiology of nasopharyngeal carcinoma. A review</article-title>
          <source>Indian J Cancer</source>
          <year>1998</year>
          <volume>35</volume>
          <issue>2</issue>
          <fpage>47</fpage>
          <lpage>56</lpage>
        </citation>
        <citation citation-type="display-unstructured">Kumar S, Mahanta J (1998) Aetiology of nasopharyngeal carcinoma. A review. Indian J Cancer 35(2):47&#x2013;56 <pub-id pub-id-type="pmid">9849024</pub-id></citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yu</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Yuan</surname>
              <given-names>JM</given-names>
            </name>
          </person-group>
          <article-title>Epidemiology of nasopharyngeal carcinoma</article-title>
          <source>Semin Cancer Biol</source>
          <year>2002</year>
          <volume>12</volume>
          <issue>6</issue>
          <fpage>421</fpage>
          <lpage>429</lpage>
          <pub-id pub-id-type="doi">10.1016/S1044579X02000858</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Yu MC, Yuan JM (2002) Epidemiology of nasopharyngeal carcinoma. Semin Cancer Biol 12(6):421&#x2013;429 <pub-id pub-id-type="pmid">12450728</pub-id></citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yang</surname>
              <given-names>HY</given-names>
            </name>
            <name>
              <surname>Xiao</surname>
              <given-names>ZQ</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Establishment of 2-dE map of human low differentiation nasopharyngeal carcinoma cell line CNE-2 proteome</article-title>
          <source>Zhong Nan Da Xue Xue Bao Yi Xue Ban</source>
          <year>2004</year>
          <volume>29</volume>
          <issue>2</issue>
          <fpage>123</fpage>
          <lpage>128</lpage>
        </citation>
        <citation citation-type="display-unstructured">Yang HY, Xiao ZQ, Li F (2004) Establishment of 2-dE map of human low differentiation nasopharyngeal carcinoma cell line CNE-2 proteome. Zhong Nan Da Xue Xue Bao Yi Xue Ban 29(2):123&#x2013;128 <pub-id pub-id-type="pmid">16145891</pub-id></citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jiang</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Gan</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Proteome analysis of antiproliferative mechanism of 12-<italic>O</italic>-tetradecanoylphorbol 13-acetate on cultured nasopharyngeal carcinoma CNE2 cells</article-title>
          <source>J Proteome Res</source>
          <year>2005</year>
          <volume>4</volume>
          <issue>2</issue>
          <fpage>599</fpage>
          <lpage>605</lpage>
          <pub-id pub-id-type="doi">10.1021/pr0497677</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Jiang P, Gan M, Huang H et&#xA0;al (2005) Proteome analysis of antiproliferative mechanism of 12-O-tetradecanoylphorbol 13-acetate on cultured nasopharyngeal carcinoma CNE2 cells. J Proteome Res 4(2):599&#x2013;605 <pub-id pub-id-type="pmid">15822940</pub-id></citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Xiao</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A reference map of human nasopharyngeal squamous carcinoma proteome</article-title>
          <source>Int J Oncol</source>
          <year>2007</year>
          <volume>30</volume>
          <issue>5</issue>
          <fpage>1077</fpage>
          <lpage>1088</lpage>
        </citation>
        <citation citation-type="display-unstructured">Li F, Xiao Z, Zhang P et&#xA0;al (2007) A reference map of human nasopharyngeal squamous carcinoma proteome. Int J Oncol 30(5):1077&#x2013;1088 <pub-id pub-id-type="pmid">17390009</pub-id></citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tan</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Proteomic analysis of differential protein expression in human nasopharyngeal carcinoma cells induced by NAG7 transfection</article-title>
          <source>Proteomics</source>
          <year>2002</year>
          <volume>2</volume>
          <issue>3</issue>
          <fpage>306</fpage>
          <lpage>312</lpage>
          <pub-id pub-id-type="doi">10.1002/1615-9861(200203)2:3&lt;306::AID-PROT306&gt;3.0.CO;2-#</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Tan C, Li J, Wang J et&#xA0;al (2002) Proteomic analysis of differential protein expression in human nasopharyngeal carcinoma cells induced by NAG7 transfection. Proteomics 2(3):306&#x2013;312 <pub-id pub-id-type="pmid">11921446</pub-id></citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sun</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Yi</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>PF</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Identification of differential proteins in nasopharyngeal carcinoma cells with p53 silence by proteome analysis</article-title>
          <source>FEBS Lett</source>
          <year>2007</year>
          <volume>581</volume>
          <issue>1</issue>
          <fpage>131</fpage>
          <lpage>139</lpage>
          <pub-id pub-id-type="doi">10.1016/j.febslet.2006.12.008</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Sun Y, Yi H, Zhang PF et&#xA0;al (2007) Identification of differential proteins in nasopharyngeal carcinoma cells with p53 silence by proteome analysis. FEBS Lett 581(1):131&#x2013;139 <pub-id pub-id-type="pmid">17184779</pub-id></citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sun</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>do</surname>
              <given-names>N</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Aberrant methylation of CDH13 gene in nasopharyngeal carcinoma could serve as a potential diagnostic biomarker</article-title>
          <source>Oral Oncol</source>
          <year>2007</year>
          <volume>43</volume>
          <issue>1</issue>
          <fpage>82</fpage>
          <lpage>87</lpage>
          <pub-id pub-id-type="doi">10.1016/j.oraloncology.2006.01.007</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Sun D, Zhang Z, Van do N et&#xA0;al (2007) Aberrant methylation of CDH13 gene in nasopharyngeal carcinoma could serve as a potential diagnostic biomarker. Oral Oncol 43(1):82&#x2013;87 <pub-id pub-id-type="pmid">16807071</pub-id></citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Doustjalali</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Yusof</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Govindasamy</surname>
              <given-names>GK</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Patients with nasopharyngeal carcinoma demonstrate enhanced serum and tissue ceruloplasmin expression</article-title>
          <source>J Med Invest</source>
          <year>2006</year>
          <volume>53</volume>
          <issue>1&#x2013;2</issue>
          <fpage>20</fpage>
          <lpage>28</lpage>
          <pub-id pub-id-type="doi">10.2152/jmi.53.20</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Doustjalali SR, Yusof R, Govindasamy GK et&#xA0;al (2006) Patients with nasopharyngeal carcinoma demonstrate enhanced serum and tissue ceruloplasmin expression. J Med Invest 53(1&#x2013;2):20&#x2013;28 <pub-id pub-id-type="pmid">16537992</pub-id></citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Weinkauf</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hiddemann</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Dreyling</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Sample pooling in 2-D gel electrophoresis: a new approach to reduce nonspecific expression background</article-title>
          <source>Electrophoresis</source>
          <year>2006</year>
          <volume>27</volume>
          <issue>22</issue>
          <fpage>4555</fpage>
          <lpage>4558</lpage>
          <pub-id pub-id-type="doi">10.1002/elps.200600207</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Weinkauf M, Hiddemann W, Dreyling M (2006) Sample pooling in 2-D gel electrophoresis: a new approach to reduce nonspecific expression background. Electrophoresis 27(22):4555&#x2013;4558 <pub-id pub-id-type="pmid">17066383</pub-id></citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ramagli</surname>
              <given-names>LS</given-names>
            </name>
          </person-group>
          <article-title>Quantifying protein in 2-D PAGE solubilization buffers</article-title>
          <source>Methods Mol Biol</source>
          <year>1999</year>
          <volume>112</volume>
          <fpage>99</fpage>
          <lpage>103</lpage>
        </citation>
        <citation citation-type="display-unstructured">Ramagli LS (1999) Quantifying protein in 2-D PAGE solubilization buffers. Methods Mol Biol 112:99&#x2013;103 <pub-id pub-id-type="pmid">10027233</pub-id></citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yan</surname>
              <given-names>JX</given-names>
            </name>
            <name>
              <surname>Wait</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Berkelman</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A modified silver staining protocol for visualization of proteins compatible with matrix-assisted laser desorption/ionization and electrospray ionization-mass spectrometry</article-title>
          <source>Electrophoresis</source>
          <year>2000</year>
          <volume>21</volume>
          <issue>17</issue>
          <fpage>3666</fpage>
          <lpage>3672</lpage>
          <pub-id pub-id-type="doi">10.1002/1522-2683(200011)21:17&lt;3666::AID-ELPS3666&gt;3.0.CO;2-6</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Yan JX, Wait R, Berkelman T et&#xA0;al (2000) A modified silver staining protocol for visualization of proteins compatible with matrix-assisted laser desorption/ionization and electrospray ionization-mass spectrometry. Electrophoresis 21(17):3666&#x2013;3672 <pub-id pub-id-type="pmid">11271485</pub-id></citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jackson</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Alexandrov</surname>
              <given-names>AB</given-names>
            </name>
            <name>
              <surname>Gribben</surname>
              <given-names>SC</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Expression and shedding of ICAM-1 in bladder cancer and its immunotherapy</article-title>
          <source>Int J Cancer</source>
          <year>1993</year>
          <volume>55</volume>
          <issue>6</issue>
          <fpage>921</fpage>
          <lpage>925</lpage>
          <pub-id pub-id-type="doi">10.1002/ijc.2910550608</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Jackson AM, Alexandrov AB, Gribben SC et&#xA0;al (1993) Expression and shedding of ICAM-1 in bladder cancer and its immunotherapy. Int J Cancer 55(6):921&#x2013;925 <pub-id pub-id-type="pmid">7902828</pub-id></citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Santarosa</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Favaro</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Quaia</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Expression and release of intercellular adhesion molecule-1 in renal-cancer patients</article-title>
          <source>Int J Cancer</source>
          <year>1995</year>
          <volume>62</volume>
          <issue>3</issue>
          <fpage>271</fpage>
          <lpage>275</lpage>
          <pub-id pub-id-type="doi">10.1002/ijc.2910620307</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Santarosa M, Favaro D, Quaia M et&#xA0;al (1995) Expression and release of intercellular adhesion molecule-1 in renal-cancer patients. Int J Cancer 62(3):271&#x2013;275 <pub-id pub-id-type="pmid">7628868</pub-id></citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bausserman</surname>
              <given-names>LL</given-names>
            </name>
            <name>
              <surname>Herbert</surname>
              <given-names>PN</given-names>
            </name>
            <name>
              <surname>Rodger</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Rapid clearance of serum amyloid A from high-density lipoproteins</article-title>
          <source>Biochim Biophys Acta</source>
          <year>1984</year>
          <volume>792</volume>
          <issue>2</issue>
          <fpage>186</fpage>
          <lpage>191</lpage>
        </citation>
        <citation citation-type="display-unstructured">Bausserman LL, Herbert PN, Rodger R et&#xA0;al (1984) Rapid clearance of serum amyloid A from high-density lipoproteins. Biochim Biophys Acta 792(2):186&#x2013;191 <pub-id pub-id-type="pmid">6696928</pub-id></citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Raynes</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Eagling</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>McAdam</surname>
              <given-names>KP</given-names>
            </name>
          </person-group>
          <article-title>Acute-phase protein synthesis in human hepatoma cells: differential regulation of serum amyloid A (SAA) and haptoglobin by interleukin-1 and interleukin-6</article-title>
          <source>Clin Exp Immunol</source>
          <year>1991</year>
          <volume>83</volume>
          <issue>3</issue>
          <fpage>488</fpage>
          <lpage>491</lpage>
        </citation>
        <citation citation-type="display-unstructured">Raynes JG, Eagling S, McAdam KP (1991) Acute-phase protein synthesis in human hepatoma cells: differential regulation of serum amyloid A (SAA) and haptoglobin by interleukin-1 and interleukin-6. Clin Exp Immunol 83(3):488&#x2013;491 <pub-id pub-id-type="pmid">1706240</pub-id></citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hunt</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Thomas</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Sebastian</surname>
              <given-names>LT</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Optimal replication and the importance of experimental design for gel-based quantitative proteomics</article-title>
          <source>J Proteome Res</source>
          <year>2005</year>
          <volume>4</volume>
          <issue>3</issue>
          <fpage>809</fpage>
          <lpage>819</lpage>
          <pub-id pub-id-type="doi">10.1021/pr049758y</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Hunt SM, Thomas MR, Sebastian LT et&#xA0;al (2005) Optimal replication and the importance of experimental design for gel-based quantitative proteomics. J Proteome Res 4(3):809&#x2013;819 <pub-id pub-id-type="pmid">15952727</pub-id></citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Anderson</surname>
              <given-names>NL</given-names>
            </name>
            <name>
              <surname>Anderson</surname>
              <given-names>NG</given-names>
            </name>
          </person-group>
          <article-title>The human plasma proteome: history, character, and diagnostic prospects</article-title>
          <source>Mol Cell Proteomics</source>
          <year>2002</year>
          <volume>1</volume>
          <issue>11</issue>
          <fpage>845</fpage>
          <lpage>867</lpage>
          <pub-id pub-id-type="doi">10.1074/mcp.R200007-MCP200</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Anderson NL, Anderson NG (2002) The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 1(11):845&#x2013;867 <pub-id pub-id-type="pmid">12488461</pub-id></citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Etzioni</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Urban</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Ramsey</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The case for early detection</article-title>
          <source>Nat Rev Cancer</source>
          <year>2003</year>
          <volume>3</volume>
          <issue>4</issue>
          <fpage>243</fpage>
          <lpage>252</lpage>
          <pub-id pub-id-type="doi">10.1038/nrc1041</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Etzioni R, Urban N, Ramsey S et&#xA0;al (2003) The case for early detection. Nat Rev Cancer 3(4):243&#x2013;252 <pub-id pub-id-type="pmid">12671663</pub-id></citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhang</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>AY</given-names>
            </name>
            <name>
              <surname>Loriaux</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mass spectrometric detection of tissue proteins in plasma</article-title>
          <source>Mol Cell Proteomics</source>
          <year>2007</year>
          <volume>6</volume>
          <issue>1</issue>
          <fpage>64</fpage>
          <lpage>71</lpage>
        </citation>
        <citation citation-type="display-unstructured">Zhang H, Liu AY, Loriaux P et&#xA0;al (2007) Mass spectrometric detection of tissue proteins in plasma. Mol Cell Proteomics 6(1):64&#x2013;71 <pub-id pub-id-type="pmid">17030953</pub-id></citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Anderson</surname>
              <given-names>NL</given-names>
            </name>
            <name>
              <surname>Polanski</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Pieper</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The human plasma proteome: a nonredundant list developed by combination of four separate sources</article-title>
          <source>Mol Cell Proteomics</source>
          <year>2004</year>
          <volume>3</volume>
          <issue>4</issue>
          <fpage>311</fpage>
          <lpage>326</lpage>
          <pub-id pub-id-type="doi">10.1074/mcp.M300127-MCP200</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Anderson NL, Polanski M, Pieper R et&#xA0;al (2004) The human plasma proteome: a nonredundant list developed by combination of four separate sources. Mol Cell Proteomics 3(4):311&#x2013;326 <pub-id pub-id-type="pmid">14718574</pub-id></citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Thadikkaran</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Siegenthaler</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Crettaz</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Recent advances in blood-related proteomics</article-title>
          <source>Proteomics</source>
          <year>2005</year>
          <volume>5</volume>
          <issue>12</issue>
          <fpage>3019</fpage>
          <lpage>3034</lpage>
          <pub-id pub-id-type="doi">10.1002/pmic.200402053</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Thadikkaran L, Siegenthaler MA, Crettaz D et&#xA0;al (2005) Recent advances in blood-related proteomics. Proteomics 5(12):3019&#x2013;3034 <pub-id pub-id-type="pmid">16041673</pub-id></citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nedelkov</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Kiernan</surname>
              <given-names>UA</given-names>
            </name>
            <name>
              <surname>Niederkofler</surname>
              <given-names>EE</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Investigating diversity in human plasma proteins</article-title>
          <source>Proc Natl Acad Sci USA</source>
          <year>2005</year>
          <volume>102</volume>
          <issue>31</issue>
          <fpage>10852</fpage>
          <lpage>10857</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.0500426102</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Nedelkov D, Kiernan UA, Niederkofler EE et&#xA0;al (2005) Investigating diversity in human plasma proteins. Proc Natl Acad Sci USA 102(31):10852&#x2013;10857 <pub-id pub-id-type="pmid">16043703</pub-id></citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cho</surname>
              <given-names>WC</given-names>
            </name>
            <name>
              <surname>Yip</surname>
              <given-names>TT</given-names>
            </name>
            <name>
              <surname>Yip</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Identification of serum amyloid a protein as a potentially useful biomarker to monitor relapse of nasopharyngeal cancer by serum proteomic profiling</article-title>
          <source>Clin Cancer Res</source>
          <year>2004</year>
          <volume>10</volume>
          <issue>1 Pt 1</issue>
          <fpage>43</fpage>
          <lpage>52</lpage>
          <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-0413-3</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Cho WC, Yip TT, Yip C et&#xA0;al (2004) Identification of serum amyloid a protein as a potentially useful biomarker to monitor relapse of nasopharyngeal cancer by serum proteomic profiling. Clin Cancer Res 10(1 Pt 1):43&#x2013;52 <pub-id pub-id-type="pmid">14734450</pub-id></citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Diamandis</surname>
              <given-names>EP</given-names>
            </name>
          </person-group>
          <article-title>Point: proteomic patterns in biological fluids: do they represent the future of cancer diagnostics?</article-title>
          <source>Clin Chem</source>
          <year>2003</year>
          <volume>49</volume>
          <issue>8</issue>
          <fpage>1272</fpage>
          <lpage>1275</lpage>
          <pub-id pub-id-type="doi">10.1373/49.8.1272</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Diamandis EP (2003) Point: proteomic patterns in biological fluids: do they represent the future of cancer diagnostics? Clin Chem 49(8):1272&#x2013;1275 <pub-id pub-id-type="pmid">12881441</pub-id></citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Diamandis</surname>
              <given-names>EP</given-names>
            </name>
          </person-group>
          <article-title>Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems</article-title>
          <source>J Natl Cancer Inst</source>
          <year>2004</year>
          <volume>96</volume>
          <issue>5</issue>
          <fpage>353</fpage>
          <lpage>356</lpage>
        </citation>
        <citation citation-type="display-unstructured">Diamandis EP (2004) Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J Natl Cancer Inst 96(5):353&#x2013;356 <pub-id pub-id-type="pmid">14996856</pub-id></citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Diamandis</surname>
              <given-names>EP</given-names>
            </name>
          </person-group>
          <article-title>Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations</article-title>
          <source>Mol Cell Proteomics</source>
          <year>2004</year>
          <volume>3</volume>
          <issue>4</issue>
          <fpage>367</fpage>
          <lpage>378</lpage>
          <pub-id pub-id-type="doi">10.1074/mcp.R400007-MCP200</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Diamandis EP (2004) Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations. Mol Cell Proteomics 3(4):367&#x2013;378 <pub-id pub-id-type="pmid">14990683</pub-id></citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <citation citation-type="other">Putnam RW (1975) The plasma proteins. New York Academic Press</citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Curry</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Beyond expansion: structural studies on the transport roles of human serum albumin</article-title>
          <source>Vox Sang</source>
          <year>2002</year>
          <volume>83</volume>
          <issue>Suppl 1</issue>
          <fpage>315</fpage>
          <lpage>319</lpage>
        </citation>
        <citation citation-type="display-unstructured">Curry S (2002) Beyond expansion: structural studies on the transport roles of human serum albumin. Vox Sang 83(Suppl 1):315&#x2013;319 <pub-id pub-id-type="pmid">12617161</pub-id></citation>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dea</surname>
              <given-names>MK</given-names>
            </name>
            <name>
              <surname>Hamilton-Wessler</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ader</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Albumin binding of acylated insulin (NN304) does not deter action to stimulate glucose uptake</article-title>
          <source>Diabetes</source>
          <year>2002</year>
          <volume>51</volume>
          <issue>3</issue>
          <fpage>762</fpage>
          <lpage>769</lpage>
          <pub-id pub-id-type="doi">10.2337/diabetes.51.3.762</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Dea MK, Hamilton-Wessler M, Ader M et&#xA0;al (2002) Albumin binding of acylated insulin (NN304) does not deter action to stimulate glucose uptake. Diabetes 51(3):762&#x2013;769 <pub-id pub-id-type="pmid">11872677</pub-id></citation>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schussler</surname>
              <given-names>GC</given-names>
            </name>
          </person-group>
          <article-title>The thyroxine-binding proteins</article-title>
          <source>Thyroid</source>
          <year>2000</year>
          <volume>10</volume>
          <issue>2</issue>
          <fpage>141</fpage>
          <lpage>149</lpage>
        </citation>
        <citation citation-type="display-unstructured">Schussler GC (2000) The thyroxine-binding proteins. Thyroid 10(2):141&#x2013;149 <pub-id pub-id-type="pmid">10718550</pub-id></citation>
      </ref>
      <ref id="CR32">
        <label>32.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Quero</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Colome</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Prieto</surname>
              <given-names>MR</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Determination of protein markers in human serum: analysis of protein expression in toxic oil syndrome studies</article-title>
          <source>Proteomics</source>
          <year>2004</year>
          <volume>4</volume>
          <issue>2</issue>
          <fpage>303</fpage>
          <lpage>315</lpage>
          <pub-id pub-id-type="doi">10.1002/pmic.200300630</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Quero C, Colome N, Prieto MR et&#xA0;al (2004) Determination of protein markers in human serum: analysis of protein expression in toxic oil syndrome studies. Proteomics 4(2):303&#x2013;315 <pub-id pub-id-type="pmid">14760700</pub-id></citation>
      </ref>
      <ref id="CR33">
        <label>33.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Feng</surname>
              <given-names>JT</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>YK</given-names>
            </name>
            <name>
              <surname>Song</surname>
              <given-names>HY</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Heat-shock protein 27: a potential biomarker for hepatocellular carcinoma identified by serum proteome analysis</article-title>
          <source>Proteomics</source>
          <year>2005</year>
          <volume>5</volume>
          <issue>17</issue>
          <fpage>4581</fpage>
          <lpage>4588</lpage>
          <pub-id pub-id-type="doi">10.1002/pmic.200401309</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Feng JT, Liu YK, Song HY et&#xA0;al (2005) Heat-shock protein 27: a potential biomarker for hepatocellular carcinoma identified by serum proteome analysis. Proteomics 5(17):4581&#x2013;4588 <pub-id pub-id-type="pmid">16240287</pub-id></citation>
      </ref>
      <ref id="CR34">
        <label>34.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rothlein</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Mainolfi</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Czajkowski</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A form of circulating ICAM-1 in human serum</article-title>
          <source>J Immunol</source>
          <year>1991</year>
          <volume>147</volume>
          <issue>11</issue>
          <fpage>3788</fpage>
          <lpage>3793</lpage>
        </citation>
        <citation citation-type="display-unstructured">Rothlein R, Mainolfi EA, Czajkowski M et&#xA0;al (1991) A form of circulating ICAM-1 in human serum. J Immunol 147(11):3788&#x2013;3793 <pub-id pub-id-type="pmid">1682385</pub-id></citation>
      </ref>
      <ref id="CR35">
        <label>35.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Budnik</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Grewe</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gyufko</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Analysis of the production of soluble ICAM-1 molecules by human cells</article-title>
          <source>Exp Hematol</source>
          <year>1996</year>
          <volume>24</volume>
          <issue>2</issue>
          <fpage>352</fpage>
          <lpage>359</lpage>
        </citation>
        <citation citation-type="display-unstructured">Budnik A, Grewe M, Gyufko K et&#xA0;al (1996) Analysis of the production of soluble ICAM-1 molecules by human cells. Exp Hematol 24(2):352&#x2013;359 <pub-id pub-id-type="pmid">8641365</pub-id></citation>
      </ref>
      <ref id="CR36">
        <label>36.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Harning</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Mainolfi</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Bystryn</surname>
              <given-names>JC</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Serum levels of circulating intercellular adhesion molecule 1 in human malignant melanoma</article-title>
          <source>Cancer Res</source>
          <year>1991</year>
          <volume>51</volume>
          <issue>18</issue>
          <fpage>5003</fpage>
          <lpage>5005</lpage>
        </citation>
        <citation citation-type="display-unstructured">Harning R, Mainolfi E, Bystryn JC et&#xA0;al (1991) Serum levels of circulating intercellular adhesion molecule 1 in human malignant melanoma. Cancer Res 51(18):5003&#x2013;5005 <pub-id pub-id-type="pmid">1680025</pub-id></citation>
      </ref>
      <ref id="CR37">
        <label>37.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Grothey</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Heistermann</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Philippou</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Serum levels of soluble intercellular adhesion molecule-1 (ICAM-1, CD54) in patients with non-small-cell lung cancer: correlation with histological expression of ICAM-1 and tumour stage</article-title>
          <source>Br J Cancer</source>
          <year>1998</year>
          <volume>77</volume>
          <issue>5</issue>
          <fpage>801</fpage>
          <lpage>807</lpage>
        </citation>
        <citation citation-type="display-unstructured">Grothey A, Heistermann P, Philippou S et&#xA0;al (1998) Serum levels of soluble intercellular adhesion molecule-1 (ICAM-1, CD54) in patients with non-small-cell lung cancer: correlation with histological expression of ICAM-1 and tumour stage. Br J Cancer 77(5):801&#x2013;807 <pub-id pub-id-type="pmid">9514061</pub-id></citation>
      </ref>
      <ref id="CR38">
        <label>38.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhang</surname>
              <given-names>GJ</given-names>
            </name>
            <name>
              <surname>Adachi</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>Serum levels of soluble intercellular adhesion molecule-1 and E-selectin in metastatic breast carcinoma: correlations with clinicopathological features and prognosis</article-title>
          <source>Int J Oncol</source>
          <year>1999</year>
          <volume>14</volume>
          <issue>1</issue>
          <fpage>71</fpage>
          <lpage>77</lpage>
        </citation>
        <citation citation-type="display-unstructured">Zhang GJ, Adachi I (1999) Serum levels of soluble intercellular adhesion molecule-1 and E-selectin in metastatic breast carcinoma: correlations with clinicopathological features and prognosis. Int J Oncol 14(1):71&#x2013;77 <pub-id pub-id-type="pmid">9863011</pub-id></citation>
      </ref>
      <ref id="CR39">
        <label>39.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nakata</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Hori</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Sunami</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Clinical significance of serum soluble intercellular adhesion molecule 1 in gastric cancer</article-title>
          <source>Clin Cancer Res</source>
          <year>2006</year>
          <volume>6</volume>
          <issue>3</issue>
          <fpage>1175</fpage>
          <lpage>1179</lpage>
        </citation>
        <citation citation-type="display-unstructured">Nakata B, Hori T, Sunami T et&#xA0;al (2006) Clinical significance of serum soluble intercellular adhesion molecule 1 in gastric cancer. Clin Cancer Res 6(3):1175&#x2013;1179 <pub-id pub-id-type="pmid">10741749</pub-id></citation>
      </ref>
      <ref id="CR40">
        <label>40.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shimizu</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Minemura</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Tsukishiro</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Serum concentration of intercellular adhesion molecule-1 in patients with hepatocellular carcinoma is a marker of the disease progression and prognosis</article-title>
          <source>Hepatology</source>
          <year>1995</year>
          <volume>22</volume>
          <issue>2</issue>
          <fpage>525</fpage>
          <lpage>531</lpage>
        </citation>
        <citation citation-type="display-unstructured">Shimizu Y, Minemura M, Tsukishiro T et&#xA0;al (1995) Serum concentration of intercellular adhesion molecule-1 in patients with hepatocellular carcinoma is a marker of the disease progression and prognosis. Hepatology 22(2):525&#x2013;531 <pub-id pub-id-type="pmid">7543436</pub-id></citation>
      </ref>
      <ref id="CR41">
        <label>41.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kitagawa</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Matsumoto</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Iriyama</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Serum cell adhesion molecules in patients with colorectal cancer</article-title>
          <source>Surg Today</source>
          <year>1998</year>
          <volume>28</volume>
          <issue>3</issue>
          <fpage>262</fpage>
          <lpage>267</lpage>
          <pub-id pub-id-type="doi">10.1007/s005950050118</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Kitagawa T, Matsumoto K, Iriyama K (1998) Serum cell adhesion molecules in patients with colorectal cancer. Surg Today 28(3):262&#x2013;267 <pub-id pub-id-type="pmid">9548306</pub-id></citation>
      </ref>
      <ref id="CR42">
        <label>42.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yoo</surname>
              <given-names>NC</given-names>
            </name>
            <name>
              <surname>Chung</surname>
              <given-names>HC</given-names>
            </name>
            <name>
              <surname>Chung</surname>
              <given-names>HC</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Synchronous elevation of soluble intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) correlates with gastric cancer progression</article-title>
          <source>Yonsei Med J</source>
          <year>1998</year>
          <volume>39</volume>
          <issue>1</issue>
          <fpage>27</fpage>
          <lpage>36</lpage>
        </citation>
        <citation citation-type="display-unstructured">Yoo NC, Chung HC, Chung HC et&#xA0;al (1998) Synchronous elevation of soluble intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) correlates with gastric cancer progression. Yonsei Med J 39(1):27&#x2013;36 <pub-id pub-id-type="pmid">9529982</pub-id></citation>
      </ref>
      <ref id="CR43">
        <label>43.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Becker</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Termeer</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Schmidt</surname>
              <given-names>RE</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Soluble intercellular adhesion molecule-1 inhibits MHC-restricted specific T cell/tumor interaction</article-title>
          <source>J Immunol</source>
          <year>1993</year>
          <volume>151</volume>
          <issue>12</issue>
          <fpage>7224</fpage>
          <lpage>7232</lpage>
        </citation>
        <citation citation-type="display-unstructured">Becker JC, Termeer C, Schmidt RE et&#xA0;al (1993) Soluble intercellular adhesion molecule-1 inhibits MHC-restricted specific T cell/tumor interaction. J Immunol 151(12):7224&#x2013;7232 <pub-id pub-id-type="pmid">7903103</pub-id></citation>
      </ref>
      <ref id="CR44">
        <label>44.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>d&#x2019;Eril</surname>
              <given-names>GM</given-names>
            </name>
            <name>
              <surname>Anesi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Maggiore</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Biological variation of serum amyloid A in healthy subjects</article-title>
          <source>Clin Chem</source>
          <year>2001</year>
          <volume>47</volume>
          <issue>8</issue>
          <fpage>1498</fpage>
          <lpage>1499</lpage>
        </citation>
        <citation citation-type="display-unstructured">d&#x2019;Eril GM, Anesi A, Maggiore M et&#xA0;al (2001) Biological variation of serum amyloid A in healthy subjects. Clin Chem 47(8):1498&#x2013;1499 <pub-id pub-id-type="pmid">11468251</pub-id></citation>
      </ref>
      <ref id="CR45">
        <label>45.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kimura</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Tomita</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Imai</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Significance of serum amyloid A on the prognosis in patients with renal cell carcinoma</article-title>
          <source>Cancer</source>
          <year>2001</year>
          <volume>92</volume>
          <issue>8</issue>
          <fpage>2072</fpage>
          <lpage>2075</lpage>
          <pub-id pub-id-type="doi">10.1002/1097-0142(20011015)92:8&lt;2072::AID-CNCR1547&gt;3.0.CO;2-P</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Kimura M, Tomita Y, Imai T et&#xA0;al (2001) Significance of serum amyloid A on the prognosis in patients with renal cell carcinoma. Cancer 92(8):2072&#x2013;2075 <pub-id pub-id-type="pmid">11596022</pub-id></citation>
      </ref>
      <ref id="CR46">
        <label>46.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Glojnaric</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Casl</surname>
              <given-names>MT</given-names>
            </name>
            <name>
              <surname>Simic</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Serum amyloid A protein (SAA) in colorectal carcinoma</article-title>
          <source>Clin Chem Lab Med</source>
          <year>2001</year>
          <volume>39</volume>
          <issue>2</issue>
          <fpage>129</fpage>
          <lpage>133</lpage>
          <pub-id pub-id-type="doi">10.1515/CCLM.2001.022</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Glojnaric I, Casl MT, Simic D et&#xA0;al (2001) Serum amyloid A protein (SAA) in colorectal carcinoma. Clin Chem Lab Med 39(2):129&#x2013;133 <pub-id pub-id-type="pmid">11341746</pub-id></citation>
      </ref>
      <ref id="CR47">
        <label>47.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Biran</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Friedman</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Neumann</surname>
              <given-names>L</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Serum amyloid A (SAA) variations in patients with cancer: correlation with disease activity, stage, primary site, and prognosis</article-title>
          <source>J Clin Pathol</source>
          <year>1986</year>
          <volume>39</volume>
          <issue>7</issue>
          <fpage>794</fpage>
          <lpage>797</lpage>
          <pub-id pub-id-type="doi">10.1136/jcp.39.7.794</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Biran H, Friedman N, Neumann L et&#xA0;al (1986) Serum amyloid A (SAA) variations in patients with cancer: correlation with disease activity, stage, primary site, and prognosis. J Clin Pathol 39(7):794&#x2013;797 <pub-id pub-id-type="pmid">3734116</pub-id></citation>
      </ref>
      <ref id="CR48">
        <label>48.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Benson</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Cohen</surname>
              <given-names>AS</given-names>
            </name>
          </person-group>
          <article-title>Serum amyloid A protein in amyloidosis, rheumatic, and enoplastic diseases</article-title>
          <source>Arthritis Rheum</source>
          <year>1979</year>
          <volume>22</volume>
          <issue>1</issue>
          <fpage>36</fpage>
          <lpage>42</lpage>
          <pub-id pub-id-type="doi">10.1002/art.1780220106</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Benson MD, Cohen AS (1979) Serum amyloid A protein in amyloidosis, rheumatic, and enoplastic diseases. Arthritis Rheum 22(1):36&#x2013;42 <pub-id pub-id-type="pmid">103558</pub-id></citation>
      </ref>
      <ref id="CR49">
        <label>49.</label>
        <citation citation-type="other">Diamandis EP (2004) Identification of serum amyloid a protein as a potentially useful biomarker for nasopharyngeal carcinoma. Clin Cancer Res 10(15):5293; author reply-4</citation>
      </ref>
      <ref id="CR50">
        <label>50.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Urieli-Shoval</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Cohen</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Eisenberg</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Widespread expression of serum amyloid A in histologically normal human tissues. Predominant localization to the epithelium</article-title>
          <source>J Histochem Cytochem</source>
          <year>1998</year>
          <volume>46</volume>
          <issue>12</issue>
          <fpage>1377</fpage>
          <lpage>1384</lpage>
        </citation>
        <citation citation-type="display-unstructured">Urieli-Shoval S, Cohen P, Eisenberg S et&#xA0;al (1998) Widespread expression of serum amyloid A in histologically normal human tissues. Predominant localization to the epithelium. J Histochem Cytochem 46(12):1377&#x2013;1384 <pub-id pub-id-type="pmid">9815279</pub-id></citation>
      </ref>
      <ref id="CR51">
        <label>51.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lindquist</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>The heat-shock response</article-title>
          <source>Annu Rev Biochem</source>
          <year>1986</year>
          <volume>55</volume>
          <fpage>1151</fpage>
          <lpage>1191</lpage>
          <pub-id pub-id-type="doi">10.1146/annurev.bi.55.070186.005443</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Lindquist S (1986) The heat-shock response. Annu Rev Biochem 55:1151&#x2013;1191 <pub-id pub-id-type="pmid">2427013</pub-id></citation>
      </ref>
      <ref id="CR52">
        <label>52.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Subjeck</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Shyy</surname>
              <given-names>TT</given-names>
            </name>
          </person-group>
          <article-title>Stress protein systems of mammalian cells</article-title>
          <source>Am J Physiol</source>
          <year>1986</year>
          <volume>250</volume>
          <issue>1 Pt 1</issue>
          <fpage>C1</fpage>
          <lpage>C17</lpage>
        </citation>
        <citation citation-type="display-unstructured">Subjeck JR, Shyy TT (1986) Stress protein systems of mammalian cells. Am J Physiol 250(1 Pt 1):C1&#x2013;C17 <pub-id pub-id-type="pmid">3510555</pub-id></citation>
      </ref>
      <ref id="CR53">
        <label>53.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Barnes</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Dix</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Collins</surname>
              <given-names>BW</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Expression of inducible Hsp70 enhances the proliferation of MCF-7 breast cancer cells and protects against the cytotoxic effects of hyperthermia</article-title>
          <source>Cell Stress Chaperones</source>
          <year>2001</year>
          <volume>6</volume>
          <issue>4</issue>
          <fpage>316</fpage>
          <lpage>325</lpage>
          <pub-id pub-id-type="doi">10.1379/1466-1268(2001)006&lt;0316:EOIHET&gt;2.0.CO;2</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Barnes JA, Dix DJ, Collins BW et&#xA0;al (2001) Expression of inducible Hsp70 enhances the proliferation of MCF-7 breast cancer cells and protects against the cytotoxic effects of hyperthermia. Cell Stress Chaperones 6(4):316&#x2013;325 <pub-id pub-id-type="pmid">11795468</pub-id></citation>
      </ref>
      <ref id="CR54">
        <label>54.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ravagnan</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Gurbuxani</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Susin</surname>
              <given-names>SA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Heat-shock protein 70 antagonizes apoptosis-inducing factor</article-title>
          <source>Nat Cell Biol</source>
          <year>2001</year>
          <volume>3</volume>
          <issue>9</issue>
          <fpage>839</fpage>
          <lpage>843</lpage>
          <pub-id pub-id-type="doi">10.1038/ncb0901-839</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Ravagnan L, Gurbuxani S, Susin SA et&#xA0;al (2001) Heat-shock protein 70 antagonizes apoptosis-inducing factor. Nat Cell Biol 3(9):839&#x2013;843 <pub-id pub-id-type="pmid">11533664</pub-id></citation>
      </ref>
      <ref id="CR55">
        <label>55.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Clark</surname>
              <given-names>PR</given-names>
            </name>
            <name>
              <surname>Menoret</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>The inducible Hsp70 as a marker of tumor immunogenicity</article-title>
          <source>Cell Stress Chaperones</source>
          <year>2001</year>
          <volume>6</volume>
          <issue>2</issue>
          <fpage>121</fpage>
          <lpage>125</lpage>
          <pub-id pub-id-type="doi">10.1379/1466-1268(2001)006&lt;0121:TIHAAM&gt;2.0.CO;2</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Clark PR, Menoret A (2001) The inducible Hsp70 as a marker of tumor immunogenicity. Cell Stress Chaperones 6(2):121&#x2013;125 <pub-id pub-id-type="pmid">11599573</pub-id></citation>
      </ref>
      <ref id="CR56">
        <label>56.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Milicevic</surname>
              <given-names>ZT</given-names>
            </name>
            <name>
              <surname>Petkovic</surname>
              <given-names>MZ</given-names>
            </name>
            <name>
              <surname>Drndarevic</surname>
              <given-names>NC</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Expression of heat shock protein 70 (HSP70) in patients with colorectal adenocarcinoma&#x2013;immunohistochemistry and Western blot analysis</article-title>
          <source>Neoplasma</source>
          <year>2007</year>
          <volume>54</volume>
          <issue>1</issue>
          <fpage>37</fpage>
          <lpage>45</lpage>
        </citation>
        <citation citation-type="display-unstructured">Milicevic ZT, Petkovic MZ, Drndarevic NC et&#xA0;al (2007) Expression of heat shock protein 70 (HSP70) in patients with colorectal adenocarcinoma&#x2013;immunohistochemistry and Western blot analysis. Neoplasma 54(1):37&#x2013;45 <pub-id pub-id-type="pmid">17233550</pub-id></citation>
      </ref>
      <ref id="CR57">
        <label>57.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lazaris</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Chatzigianni</surname>
              <given-names>EB</given-names>
            </name>
            <name>
              <surname>Panoussopoulos</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Proliferating cell nuclear antigen and heat shock protein 70 immunolocalization in invasive ductal breast cancer not otherwise specified</article-title>
          <source>Breast Cancer Res Treat</source>
          <year>1997</year>
          <volume>43</volume>
          <issue>1</issue>
          <fpage>43</fpage>
          <lpage>51</lpage>
          <pub-id pub-id-type="doi">10.1023/A:1005706110275</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Lazaris A, Chatzigianni EB, Panoussopoulos D et&#xA0;al (1997) Proliferating cell nuclear antigen and heat shock protein 70 immunolocalization in invasive ductal breast cancer not otherwise specified. Breast Cancer Res Treat 43(1):43&#x2013;51 <pub-id pub-id-type="pmid">9065598</pub-id></citation>
      </ref>
      <ref id="CR58">
        <label>58.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Torronteguy</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Frasson</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Zerwes</surname>
              <given-names>F</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Inducible heat shock protein 70 expression as a potential predictive marker of metastasis in breast tumors</article-title>
          <source>Cell Stress Chaperones</source>
          <year>2006</year>
          <volume>11</volume>
          <issue>1</issue>
          <fpage>34</fpage>
          <lpage>43</lpage>
          <pub-id pub-id-type="doi">10.1379/CSC-159R.1</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Torronteguy C, Frasson A, Zerwes F et&#xA0;al (2006) Inducible heat shock protein 70 expression as a potential predictive marker of metastasis in breast tumors. Cell Stress Chaperones 11(1):34&#x2013;43 <pub-id pub-id-type="pmid">16572727</pub-id></citation>
      </ref>
      <ref id="CR59">
        <label>59.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Abe</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Manola</surname>
              <given-names>JB</given-names>
            </name>
            <name>
              <surname>Oh</surname>
              <given-names>WK</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Plasma levels of heat shock protein 70 in patients with prostate cancer: a potential biomarker for prostate cancer</article-title>
          <source>Clin Prostate Cancer</source>
          <year>2004</year>
          <volume>3</volume>
          <issue>1</issue>
          <fpage>49</fpage>
          <lpage>53</lpage>
        </citation>
        <citation citation-type="display-unstructured">Abe M, Manola JB, Oh WK et&#xA0;al (2004) Plasma levels of heat shock protein 70 in patients with prostate cancer: a potential biomarker for prostate cancer. Clin Prostate Cancer 3(1):49&#x2013;53 <pub-id pub-id-type="pmid">15279691</pub-id></citation>
      </ref>
      <ref id="CR60">
        <label>60.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chuma</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Sakamoto</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Yamazaki</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Expression profiling in multistage hepatocarcinogenesis: identification of HSP70 as a molecular marker of early hepatocellular carcinoma</article-title>
          <source>Hepatology</source>
          <year>2003</year>
          <volume>37</volume>
          <issue>1</issue>
          <fpage>198</fpage>
          <lpage>207</lpage>
          <pub-id pub-id-type="doi">10.1053/jhep.2003.50022</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Chuma M, Sakamoto M, Yamazaki K et&#xA0;al (2003) Expression profiling in multistage hepatocarcinogenesis: identification of HSP70 as a molecular marker of early hepatocellular carcinoma. Hepatology 37(1):198&#x2013;207 <pub-id pub-id-type="pmid">12500205</pub-id></citation>
      </ref>
      <ref id="CR61">
        <label>61.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lazaris</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Theodoropoulos</surname>
              <given-names>GE</given-names>
            </name>
            <name>
              <surname>Aroni</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Immunohistochemical expression of C-myc oncogene, heat shock protein 70 and HLA-DR molecules in malignant cutaneous melanoma</article-title>
          <source>Virchows Arch</source>
          <year>1995</year>
          <volume>426</volume>
          <issue>5</issue>
          <fpage>461</fpage>
          <lpage>467</lpage>
          <pub-id pub-id-type="doi">10.1007/BF00193169</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Lazaris AC, Theodoropoulos GE, Aroni K et&#xA0;al (1995) Immunohistochemical expression of C-myc oncogene, heat shock protein 70 and HLA-DR molecules in malignant cutaneous melanoma. Virchows Arch 426(5):461&#x2013;467 <pub-id pub-id-type="pmid">7633656</pub-id></citation>
      </ref>
      <ref id="CR62">
        <label>62.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kaur</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Das</surname>
              <given-names>SN</given-names>
            </name>
            <name>
              <surname>Srivastava</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Cell surface expression of 70 kDa heat shock protein in human oral dysplasia and squamous cell carcinoma: correlation with clinicopathological features</article-title>
          <source>Oral Oncol</source>
          <year>1998</year>
          <volume>34</volume>
          <issue>2</issue>
          <fpage>93</fpage>
          <lpage>98</lpage>
          <pub-id pub-id-type="doi">10.1016/S1368-8375(97)00055-9</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Kaur J, Das SN, Srivastava A et&#xA0;al (1998) Cell surface expression of 70 kDa heat shock protein in human oral dysplasia and squamous cell carcinoma: correlation with clinicopathological features. Oral Oncol 34(2):93&#x2013;98 <pub-id pub-id-type="pmid">9682770</pub-id></citation>
      </ref>
      <ref id="CR63">
        <label>63.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Volm</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Koomagi</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Mattern</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Protein expression profile of primary human squamous cell lung carcinomas indicative of the incidence of metastases</article-title>
          <source>Clin Exp Metastasis</source>
          <year>2002</year>
          <volume>19</volume>
          <issue>5</issue>
          <fpage>385</fpage>
          <lpage>390</lpage>
          <pub-id pub-id-type="doi">10.1023/A:1016361924216</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Volm M, Koomagi R, Mattern J et&#xA0;al (2002) Protein expression profile of primary human squamous cell lung carcinomas indicative of the incidence of metastases. Clin Exp Metastasis 19(5):385&#x2013;390 <pub-id pub-id-type="pmid">12198766</pub-id></citation>
      </ref>
      <ref id="CR64">
        <label>64.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mambula</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Calderwood</surname>
              <given-names>SK</given-names>
            </name>
          </person-group>
          <article-title>Heat induced release of Hsp70 from prostate carcinoma cells involves both active secretion and passive release from necrotic cells</article-title>
          <source>Int J Hyperthermia</source>
          <year>2006</year>
          <volume>22</volume>
          <issue>7</issue>
          <fpage>575</fpage>
          <lpage>585</lpage>
          <pub-id pub-id-type="doi">10.1080/02656730600976042</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Mambula SS, Calderwood SK (2006) Heat induced release of Hsp70 from prostate carcinoma cells involves both active secretion and passive release from necrotic cells. Int J Hyperthermia 22(7):575&#x2013;585 <pub-id pub-id-type="pmid">17079215</pub-id></citation>
      </ref>
      <ref id="CR65">
        <label>65.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mambula</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Calderwood</surname>
              <given-names>SK</given-names>
            </name>
          </person-group>
          <article-title>Heat shock protein 70 is secreted from tumor cells by a nonclassical pathway involving lysosomal endosomes</article-title>
          <source>J Immunol</source>
          <year>2006</year>
          <volume>177</volume>
          <issue>11</issue>
          <fpage>7849</fpage>
          <lpage>7857</lpage>
        </citation>
        <citation citation-type="display-unstructured">Mambula SS, Calderwood SK (2006) Heat shock protein 70 is secreted from tumor cells by a nonclassical pathway involving lysosomal endosomes. J Immunol 177(11):7849&#x2013;7857 <pub-id pub-id-type="pmid">17114456</pub-id></citation>
      </ref>
    </ref-list>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-item>
          <term>NPC</term>
          <def>
            <p>Nasopharyngeal carcinoma</p>
          </def>
        </def-item>
        <def-item>
          <term>2D</term>
          <def>
            <p>Two-dimensional electorphoresis</p>
          </def>
        </def-item>
        <def-item>
          <term>MALDI-TOF-MS</term>
          <def>
            <p>Matrix-assisted laser desorption/ionization-time of flight-mass spectrometry</p>
          </def>
        </def-item>
        <def-item>
          <term>LNM</term>
          <def>
            <p>Lymph node metastasis</p>
          </def>
        </def-item>
        <def-item>
          <term>ICAM-1</term>
          <def>
            <p>Intercellular adhesion molecular-1</p>
          </def>
        </def-item>
        <def-item>
          <term>HSP70</term>
          <def>
            <p>Heat shock protein 70</p>
          </def>
        </def-item>
        <def-item>
          <term>SAA</term>
          <def>
            <p>Serum amyloid A1 protein</p>
          </def>
        </def-item>
        <def-item>
          <term>ELISA</term>
          <def>
            <p>Enzyme-linked immunosorbent assay</p>
          </def>
        </def-item>
        <def-item>
          <term>IHC</term>
          <def>
            <p>Immunohistochemistry</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    <fn-group>
      <fn>
        <p>Qiulin Liao and Liang Zhao authors contributed equally.</p>
      </fn>
    </fn-group>
  </back>
</article>
</pmc-articleset>